Primer on Biological Therapy of Cancer

November 4, 2004
Fairmont Hotel
San Francisco, CA

  • Register for Programs
  • Make Hotel Reservation

This program is designed for academic/industry scientists, physicians, ancillary health care professionals, technicians, graduate students and fellows who desire a concise update of selected current scientific paradigms and challenges that exist in the biological therapy of cancer. Academic and industry leaders in basic, translational and clinical research will provide the audience with an introduction to pre-clinical animal model studies, clinical trial development and several key scientific concepts in immunology and tumor biology that have led to new product development. Attendees will also come away with an overview of important problems that have slowed the development of more effective biological therapies and with a foundation that will facilitate critical assessment of presentations in the iSBTc Annual Meeting that follows this general education session.

Session Topics

  • Basic biology and histology of tumors
  • A comparison of animal tumor models in cancer research
  • Imaging tumors and metastases for treatment evaluation
  • Principles of monoclonal antibody product development
  • Monoclonal antibodies as cancer therapy
  • Principles of adjuvant and cancer vaccine development
  • Cytokines as cancer therapy
  • Tumor escape mechanisms
  • General principles of clinical trial development

Program Committee:

Robert O. Dillman, MD
Hoag Cancer Center
Newport Beach, CA

Elizabeth A. Repasky, PhD
Roswell Park Cancer Institute
Buffalo, NY

7:00-8:00am Registration/breakfast
8:00–8:10am Introduction and Goals of the Primer
Co-Chairs:
Dr. Elizabeth Repasky and
Dr. Robert Dillman
8:10–8:40am Tumor Models: Patterns of Growth and Response to Therapy
Bonnie Hylander, PhD
8:40–8:50am Questions and Discussion
8:50–9:35am Rainbow Imaging: Cell Biology in vivo
Robert Hoffman, PhD
9:35–9:45am Questions and Discussion
9:45–10:00am Break with refreshments
10:00–10:40am Tumor Hypoxia and Other Physiological Barriers to Effective Biological Therapy
Mark Dewhirst, DVM, PhD
10:40–10:50am Questions and Discussion
10:50–11:35am Mechanisms and Uses of Monoclonal Antibodies
Paul Sondel, MD
11:35–11:45am Questions and Discussion
11:50am-12:35pm Monoclonal Antibodies in Cancer Therapy (with Box Lunches)
Ralph Schwall, PhD
12:35– 2:50pm Questions and Discussion
12:50–1:00pm Break
1:00–1:40pm Targeting Tumor Antigens by Redirecting T Cells Using Bispecific Antibodies
Lawrence Lum, MD
1:40–1:50pm Questions and Discussion
1:50–2:35pm Cytokines as Cancer Therapy
Jan Dutcher, MD
2:35–2:45pm Questions and Discussion
2:45–3:30pm Therapeutic Approaches with Immune Cells
Robert Dillman, MD
3:30–3:45pm Questions and Discussion
3:45–4:00pm Break with Refreshments
4:00–4:45pm Melanoma – Evolution as a Model for Biological Therapy
Peter Hersey, MD
4:45–4:55pm Questions and Discussion
4:55– 5:35pm Role of Antigenic Profile Changes in Tumor Escape Mechanisms
Soldano Ferrone, MD, PhD
5:35–5:45pm Question and Discussion
5:45 pm ADJOURN

Confirmed Sponsors

bristol-myers corixa